SALT LAKE CITY, March 18, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation that its application to list the Company’s common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group. The Company’s common stock is expected to begin trading on the NASDAQ Capital Market on or about March 21, 2014, under its current trading symbol “LPCN”.
Help employers find you! Check out all the jobs and post your resume.
